Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients
Last updated on April 2022Recruitment
- Recruitment Status
- Unknown status
Inclusion Criteria
- Children and young adults, ages between 0-25 who were diagnosed with T1D no more than 3 years prior to enrollment.
- Children and young adults, ages between 0-25 who were diagnosed with T1D no more than 3 years prior to enrollment.
Exclusion Criteria
- none
- none
Summary
- Conditions
- Type I Diabetes
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Younger than 25 years
- Gender
- Both males and females
Description
To obtain proof-of-principle of our approach we have initiated tight collaboration between the Laboratory of Immunology at MIGAL Galilee Research Institute, Kiryat Shmona (MIGAL) and Breinin Center for Type 1 Diabetes and Endocrinology at the Ziv Medical Center in Safed (Ziv). In this study we will ...
To obtain proof-of-principle of our approach we have initiated tight collaboration between the Laboratory of Immunology at MIGAL Galilee Research Institute, Kiryat Shmona (MIGAL) and Breinin Center for Type 1 Diabetes and Endocrinology at the Ziv Medical Center in Safed (Ziv). In this study we will first identify carriers of the HLA-A0201 allele among pediatric and young adult T1D patients at Ziv. We will then screen the T cell pool in the peripheral blood samples of these patients for CD8 T cells reactive against any of 3 known HLA-A0201-binding peptides associated with autoreactivity in T1D: Insulin beta chain 10-18, IGRP 265-73 and IGRP 222-230. The influenza virus-derived peptide MP 58-66 will serve as reference. Next we will isolate polyclonal CD8 T cells from blood samples of the same patients, activate and expand them ex-vivo and transfect them via electroporation with in-vitro-transcribed mRNA encoding the respective peptide/MHC/CD3-zeta construct(s). We will then perform co-culture experiments assessing the ability of the mRNA-transfected T cells to kill the autoreactive T cells of the same patient in a peptide-selective manner.
Inclusion Criteria
- Children and young adults, ages between 0-25 who were diagnosed with T1D no more than 3 years prior to enrollment.
- Children and young adults, ages between 0-25 who were diagnosed with T1D no more than 3 years prior to enrollment.
Exclusion Criteria
- none
- none
Tracking Information
- NCT #
- NCT02117518
- Collaborators
- Ziv Medical Center
- Investigators
- Study Director: Gideon Gross, PhD Migal Galilee Research Institute Principal Investigator: Orna Gottfried, MD Ziv Medical Center
- Study Director: Gideon Gross, PhD Migal Galilee Research Institute Orna Gottfried, MD Ziv Medical Center
Get Well Soon